What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved semaglutide products include Wegovy for chronic weight management and cardiovascular-risk reduction in certain adults, Ozempic for type 2 diabetes and related risk reduction, and Rybelsus as an oral semaglutide product for type 2 diabetes. A patient's selected semaglutide option as a preference that requires licensed clinician review. Compounded semaglutide is not the same as an FDA-approved branded product.

How It Works

Semaglutide activates GLP-1 receptors involved in appetite, satiety, insulin secretion, glucagon regulation, and gastric emptying. In weight-management contexts, GLP-1 signaling can reduce appetite and help patients feel full sooner when used alongside nutrition, activity, and clinical monitoring. Semaglutide is not a guaranteed weight-loss outcome.

What It’s Studied For

Semaglutide has been studied extensively for type 2 diabetes, chronic weight management, cardiometabolic risk reduction, and related obesity-associated outcomes. FDA-approved semaglutide products have gone through formal drug-development and labeling review, while compounded semaglutide products are not FDA-approved and have separate quality, dosing, and safety considerations.

How It May Be Used in a Clinician-Supervised Program

In a clinician-supervised program, semaglutide may be considered for patients seeking weight-management support when clinically appropriate. The clinician reviews BMI, weight history, prior medication use, current medications, diabetes history, gastrointestinal history, gallbladder or pancreatitis history, pregnancy status, thyroid cancer/MEN2 history, and other safety factors. Lifestyle changes remain part of the program.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Common gastrointestinal effects can include nausea, vomiting, diarrhea, constipation, and abdominal pain.
• Reported risks include dehydration, gallbladder problems, pancreatitis warnings, and hypoglycemia when combined with insulin or sulfonylureas.
• FDA-approved GLP-1 labels include avoidance language for personal or family history of medullary thyroid carcinoma or MEN2.
• Disclose pregnancy plans, breastfeeding, kidney disease, gastrointestinal disease, and all medications.
• FDA has reported dosing errors associated with compounded injectable semaglutide products.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions